Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Bristol-Myers Squibb
Eli Lilly and Company
Upon determination of eligibility, neo-adjuvant patients will be randomly assigned to one of two treatment arms:
* ARM A Paclitaxel + Carboplatin + Radiation Therapy + Surgery
* ARM B Paclitaxel + Carboplatin + Surgery
After surgery neo-adjuvant patients with a complete resection will either receive Paclitaxel + Carboplatin or no therapy, depending on their stage of disease at time of enrollment. Patients with incomplete resection Paclitaxel + Carboplatin + Radiation Therapy. Adjuvant patients who enter the study after complete resection will receive Paclitaxel + Carboplatin with or without Radiation Therapy based on initial stage of disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Non-small cell lung cancer
Neoadjuvant candidates must have potentially resectable disease
Adjuvant candidates must have had complete resection
Clinical stage IB, II, or IIIA non-small cell lung cancer
ECOG performance status 0 or 1
Adequate bone marrow, liver and kidney function
No previous chemotherapy or radiation therapy for non-small cell lung cancer.
Give written informed consent.
You may not be if
You cannot participate in this study if any of the following apply to you:
Stage IIIA with N2 nodes \> 6 cm
Stage IIIB or IV disease
Age \<18 years
ECOG performance status 2 or higher
Considered inoperable based on general medical condition